Prolactin receptor status as a risk factor for progression from gestational diabetes to type 2 diabetes
Summary
This study will determine whether presence of a specific gene may increase the risk of developing diabetes in women who were first found to have gestational diabetes during their pregnancy.
Diabetes first identified during pregnancy, more commonly referred to as gestational diabetes (GDM), is relatively common, affecting up to 20% of pregnancies. It is associated with an increased risk of both maternal and neonatal complications. Importantly, GDM is a major risk factor for the postpartum development of pre-diabetes or type 2 diabetes (T2D). Specifically, half of women with gestational diabetes will develop pre-diabetes or T2D within 10 years of delivery. Currently, we don’t have a clear understanding of why some women with a history of GDM progress to T2D postpartum while some may take years to progress to T2D. A clearer understanding of the risk factors for the GDM-to-T2D progression will help us identify high risk individuals and allow us to find a strategy to delay or prevent this progression.
This study will test whether the presence of a specific gene, which, so far, has no known health effect in humans, is a risk factor for GDM-to-T2D progression.
Eligibility
Eligible ages: 18 to 45
Accepts healthy participants: Yes
Inclusion criteria:
Inclusion Criteria:
1. Pregnant individuals age ≥ 18 years at time of recruitment
2. A diagnosis of gestational diabetes by the Diabetes Canada Clinical Practice Guidelines (including both the preferred or alternate testing approaches)
• Have any of the following:
o Have an elevated fasting glucose (≥5.3 mmol/L) on the diagnostic 75g OGTT in pregnancy
o Required insulin or metformin for treatment during pregnancy
o Body mass index (BMI) ≥ 25 kg/m2, yes/no (<27 weeks gestation BMI of ≥25 kg/m2 or ≥27 weeks gestation predicted BMI of ≥ 25 kg/m2 using (current weight in kg – 10kg)/height in meters2)
3. Non-pregnant individuals age ≥ 18 years at time of recruitment, who have had a diagnosis of gestational diabetes in any previous pregnancy
4. Able to provide informed consent
5. Willingness to provide a saliva sample
6. Have access to email
Exclusion criteria:
Exclusion criteria:
1. Pregnant or non-pregnant individuals who have NOT had a current or previous diagnosis of gestational diabetes
2. Unable to speak and understand French or English
3. Unable to consent or declined informed consent
Participate
Additional information
Contact information
Heidi Virtanen 587-943-2751
Principal investigator:
Carol Huang
Clinical trial:
No
REB-ID:
REB23-0170